TABLE III.

Disease-free survival in trials of aromatase inhibitors

Strategy	Reference	Trial	Protocol	Follow-up (months)	Risk reduction (%)
					Relative	Absolute
Upfront	Forbes et al., 200815	ATAC	Anastrozole vs. tamoxifen	100	15	4.1
	Mouridsen, 2008a	BIG 1-98	Letrozole vs. tamoxifen	76	12	2.3
Switch	Coombes et al., 200411	IES	Tamoxifen to exemestane vs. tamoxifen	55.7	32	4.7
	Boccardo et al., 200634	ITA	Tamoxifen to anastrozole vs. tamoxifen	64	37.5	10.5
	Jonat et al., 200635	ABCSG 8/ARNO 95/ITA	Tamoxifen to anastrozole vs. tamoxifen	30	37.6	3.7
	Kaufmann et al., 200636 Kaufmann et al., 200737	ARNO 95	Tamoxifen to anastrozole vs. tamoxifen	30.1	34	4.2
Extended	Goss et al., 200310	MA. 17	Tamoxifen to letrozole vs. tamoxifen to placebo	30	42	4.6
	Jakes et al., 200538 Jakes et al., 200739	ABCSG 6a	Tamoxifen to anastrozole vs. tamoxifen to placebo	62.3	38	4.7

^aMouridsen HT. Letrozole monotherapy vs. tamoxifen monotherapy or vs. letrozole in sequence with tamoxifen for post-menopausal women with endocrine-responsive early breast cancer. Presented at the San Antonio Breast Cancer Symposium 2008; San Antonio, TX; December 10–14, 2008.

ATAC = Arimidex, Tamoxifen, Alone or in Combination; BIG = Breast International Group; ITA = Italian Tamoxifen Anastrozole trial; ABCSG = Austrian Breast and Colorectal Cancer Study Group; ARNO = Arimidex–Nolvadex trial; IES = Intergroup Exemestane Study.